Skip to content
IP Osgoode
  • ABOUT
  • OUR TEAM
    • DIRECTOR
    • MEMBERS
    • ADVISORY BOARD
    • SPONSORS
  • IPILOGUE
    • BLOG
    • IPILOGUE EDITORS
    • GOWLING WLG PRIZE
    • IPIGRAM ARCHIVE
  • INNOVATION CLINIC
    • ABOUT
    • CHATBOT
    • BECOME A CLIENT
    • CLINIC FELLOWS
    • FAQS
  • IP INTENSIVE
    • ABOUT
    • PLACEMENTS
  • RESEARCH
    • IP LAW & POLICY
    • INNOVATION
    • LAW REFORM
  • EVENTS
    • UPCOMING EVENTS
    • PAST EVENTS
  • OTHER ACTIVITIES
    • IP WRITING CHALLENGE
    Home
    >
    IP
    >
    Patents
    >
    Pharmaceutical Drugs

    Category: Pharmaceutical Drugs

    November 12, 2020in Blogs, IP, Pharmaceutical Drugs0by Editor
    678

    Pharmaceutical Counterfeiting: What is it and Current Issues with IP Regulations

    What is Pharmaceutical Counterfeiting? Counterfeit goods are an age-old consequence of economic markets. These consequences are especially troubling when raising concerns about the delivery of prescription medicines that the public…

    Read more
    July 15, 2020in Blogs, IP, Patents, Pharmaceutical Drugs0by Editor
    913

    US Pharma Company, Gilead Sciences, Expands Access to COVID-19 Treatment- Experts Remain Skeptical of Long-Term Demands

    As healthcare systems around the world continue to struggle with managing the rates of transmission and mortality in patients with COVID-19, an announcement made in late April by Dr. Anthony…

    Read more
    July 12, 2018in Innovation, IP, Patents, Pharmaceutical Drugs0by Editor
    530

    Innovating with Yesterday’s Inventions: Repurposing Drugs for New Indications

    Pharmaceutical research and development (R&D) has skyrocketed in recent years and is projected to reach even greater levels in the future. The total R&D spending has increased by 33 billion…

    Read more
    August 16, 2017in Access to Medicines, Blogs, Commercialization, Development, Innovation, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
    676

    Broken Promises: Utility Standards and Patent Applications in Canada

    The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…

    Read more
    January 11, 2017in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
    914

    What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work

    This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…

    Read more
    December 6, 2016in Blogs, IP Intensive, Patents, Pharmaceutical Drugs, Regulatory Policy0by Editor
    412

    Bringing Biologics in from the Cold: Does Canada’s IP Regime Need a Booster?

    As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property…

    Read more

    Posts navigation

    1 2 … 18
    Search
      Categories
      IP Osgoode
      © Osgoode Hall Law School, York University
      • Privacy & Legal
      Osgoode Hall Law School, York University
      Ignat Kaneff Building
      4700 Keele Street
      Toronto, Ontario  M3J 1P3
      Canada

      T:416.736.5030   F:416.736.5736